Compare Ishares Msci Italy ETF (EWI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Summit Therapeutics Inc — how do they compare? Ishares Msci Italy ETF trades at $56.3 (market cap $1.14B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 12× Ishares Msci Italy ETF's market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 2,377,947). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 53 Days and Summit Therapeutics Inc for 16 Days on average.
| EWI | SMMT | |
|---|---|---|
Market Cap | $1.14B | $13.71B |
Volume | 2,377,947 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $26.38 |
52-Week Low | $50.31 | $12.43 |
Typical Hold Time | 53 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI (iShares MSCI Italy ETF) trades at $56.32, down slightly by 0.05% with a bearish technical signal from moving averages and oscillators. The ETF provides concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU recovery investments. Recent news highlights European Central Bank rate hikes and energy price pressures affecting eurozone markets.
The outlook remains cautious due to technical bearish signals and macroeconomic headwinds from ECB tightening. Investment opportunity lies in Italy's banking consolidation and infrastructure spending, but risks include eurozone economic sentiment deterioration and persistent inflation concerns.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
